eli lilly glp-1 drugs glp 1 FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and Eli Lilly's Foundayo GLP-1 Weight

The efficacy of GLP-1 medications in weight management presents opportunities for wider application in non-diabetic groups, combating the worldwide obesity crisis

doi: 10.1186/1475-2840-13-49

Clinical trials, including phase 2 and 3 studies, have reported significant improvements in liver histology, including MASH resolution and decreased hepatic fat content, with GLP-1RA therapy (6, 7)

Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis

China Leads Market Growth with Rapid Treatment Adoption Revenue from obesity GLP-1 treatment in China is projected to exhibit strong growth with a CAGR of 25.4% through 2035, driven by rapidly increasing obesity rates in urban populations and growing consumer demand for weight management solutions

SGLT-2 inhibitors: the gap seems to be leveling off